Figure 1 From Randomized Phase Ii Clinical Trial Of Ruxolitinib Plus Jakafi ® (ruxolitinib) is indicated for treatment of intermediate or high risk myelofibrosis (mf), including primary mf, post polycythemia vera mf and post essential thrombocythemia mf in adults. Here in this 5 year final analysis, we report long term safety and efficacy results in patients treated with ruxolitinib in the comfort ii trial.
Ruxolitinib Demonstrates Clinical Activity In A Phase Ii Trial Of Here, we report final study results on longer term safety and efficacy after 5 years of rux treatment in comfort ii. methods: comfort ii is a randomized (2:1), open label phase 3 study of rux vs bat in pts with intermediate 2 or high risk primary mf, post pv mf, or post et mf. Long term findings from comfort ii, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Here, we report final study results on longer term safety and efficacy after 5 years of rux treatment in comfort ii. methods: comfort ii is a randomized (2:1), open label phase 3 study of rux vs bat in pts with intermediate 2 or high risk primary mf, post pv mf, or post et mf. Jean jacques kiladjian, md, phd from the saint louis hospital & paris diderot university, paris, france provides an overview of the comfort ii clinical trial.
Pdf Randomized Phase Ii Clinical Trial Of Ruxolitinib Plus Here, we report final study results on longer term safety and efficacy after 5 years of rux treatment in comfort ii. methods: comfort ii is a randomized (2:1), open label phase 3 study of rux vs bat in pts with intermediate 2 or high risk primary mf, post pv mf, or post et mf. Jean jacques kiladjian, md, phd from the saint louis hospital & paris diderot university, paris, france provides an overview of the comfort ii clinical trial. Learn more about the 5 year overall survival data of jakafi® (ruxolitinib) from the comfort trials in patients with intermediate or high risk myelofibrosis (mf). Here, we report final study results on longer term safety and efficacy after 5 years of rux treatment in comfort ii. methods: comfort ii is a randomized (2:1), open label phase 3 study of rux vs bat in pts with intermediate 2 or high risk primary mf, post pv mf, or post et mf. All patients received ruxolitinib in the extension phase of the study. maximum individual patient duration was 5 years. The primary and planned 3 year analyses of comfort i data demonstrated that ruxolitinib the first myelofibrosis approved therapy reduced splenomegaly and prolonged overall survival versus placebo. here, we present the final 5 year results.
Comfort 1 Trial Long Term Follow Up Impact Of Ruxolitinib On Os For Learn more about the 5 year overall survival data of jakafi® (ruxolitinib) from the comfort trials in patients with intermediate or high risk myelofibrosis (mf). Here, we report final study results on longer term safety and efficacy after 5 years of rux treatment in comfort ii. methods: comfort ii is a randomized (2:1), open label phase 3 study of rux vs bat in pts with intermediate 2 or high risk primary mf, post pv mf, or post et mf. All patients received ruxolitinib in the extension phase of the study. maximum individual patient duration was 5 years. The primary and planned 3 year analyses of comfort i data demonstrated that ruxolitinib the first myelofibrosis approved therapy reduced splenomegaly and prolonged overall survival versus placebo. here, we present the final 5 year results.
Comfort I Ii Trials On Ruxolitinib Download Table All patients received ruxolitinib in the extension phase of the study. maximum individual patient duration was 5 years. The primary and planned 3 year analyses of comfort i data demonstrated that ruxolitinib the first myelofibrosis approved therapy reduced splenomegaly and prolonged overall survival versus placebo. here, we present the final 5 year results.
Comments are closed.